REHOVOT, Israel, Oct. 18,
2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq:
EVGN) (TASE: EVGN), a leading computational biology company
targeting to revolutionize life-science product discovery and
development across multiple market segments, today provides an
update to its investors and stakeholders amidst the ongoing
security situation in Israel.
"In these trying times, we extend our heartfelt condolences to
those directly and indirectly affected by the recent events in
Israel," said Ofer Haviv, CEO of Evogene. "Despite the
challenges, Evogene and its subsidiaries remain steadfast in their
commitment to innovation and progress. Our focus and strategy
remain stable, and our dedicated team works diligently to fulfill
our missions for 2023 and pave the way for 2024. We are grateful
for the unwavering support from our partners and stakeholders. We
remain attentive and monitor our position and plans as the
situation evolves."
About Evogene Ltd.
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) is a computational
biology company leveraging big data and artificial intelligence to
revolutionize the development of life-science-based products by
utilizing cutting-edge technologies to increase the probability of
success while reducing development time and cost.
Evogene established three unique tech-engines - MicroBoost
AI, ChemPass AI and GeneRator AI. Each tech-engine is
focused on the discovery and development of products based on one
of the following core components: microbes (MicroBoost AI), small
molecules (ChemPass AI), and genetic elements (GeneRator
AI).
Evogene uses its tech-engines to develop products through
strategic partnerships and collaborations, and its five
subsidiaries include:
- Biomica Ltd. (www.biomicamed.com) developing and advancing
novel microbiome-based therapeutics to treat human disorders
powered by MicroBoost AI;
- Lavie Bio Ltd. (www.lavie-bio.com) developing and commercially
advancing microbiome-based ag-biologicals powered by MicroBoost
AI;
- AgPlenus Ltd. (www.agplenus.com) developing next-generation ag
chemicals for effective and sustainable crop protection powered by
ChemPass AI;
- Canonic Ltd. (www.canonicbio.com) developing medical cannabis
products based on decoding plant genetics for optimized therapeutic
effect powered by GeneRator AI; and
- Casterra Ag Ltd. (www.casterra.co) developing and marketing
superior castor seed varieties producing high yield and high-grade
oil content on an industrial scale for the biofuel and other
industries powered by GeneRator AI.
For more information, please visit www.evogene.com
Forward-Looking Statements
This press release contains "forward-looking statements"
relating to future events. These statements may be identified by
words such as "may", "could", "expects", "intends", "anticipates",
"plans", "believes", "scheduled", "estimates", or words of similar
meaning. For example, Evogene is using forward-looking statement in
this press release when it discusses the current security situation
in Israel and its affect on
Evogene and its subsidiaries. Such statements are based on current
expectations, estimates, projections and assumptions, describe
opinions about future events, and involve certain risks and
uncertainties (inclufing but not limited in relation to the recent
events in Israel) which are
difficult to predict and are not guarantees of future performance.
Therefore, actual future results, performance or achievements of
Evogene and its subsidiaries may differ materially from what is
expressed or implied by such forward-looking statements due to a
variety of factors, many of which are beyond the control of Evogene
and its subsidiaries, including, without limitation, those risk
factors contained in Evogene's reports filed with the applicable
securities authorities. In addition, Evogene and its subsidiaries
rely, and expect to continue to rely, on third parties to conduct
certain activities, such as their field-trials and pre-clinical
studies, and if these third parties do not successfully carry out
their contractual duties, comply with regulatory requirements or
meet expected deadlines, Evogene and its subsidiaries may
experience significant delays in the conduct of their activities.
Evogene and its subsidiaries disclaim any obligation or commitment
to update these forward-looking statements to reflect future events
or developments or changes in expectations, estimates, projections
and assumptions.
Evogene Investors' Contact:
Rachel Pomerantz Gerber, Head of Investor
Relations at Evogene
rachel.pomerantz@evogene.com
Tel: +972-8-9311901
Logo:
https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/evogene-provides-operational-update-amidst-current-security-situation-in-israel-301960433.html
SOURCE Evogene